Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 58Sarcoma 39Neoplasm Metastasis 22Neoplasms 20Ovarian Neoplasms 17Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Recurrence 7Leiomyosarcoma 7Kidney Neoplasms 7Melanoma 6Liposarcoma 6Hemangiosarcoma 6Glioblastoma 6Fallopian Tube Neoplasms 6Thyroid Neoplasms 5Prostatic Neoplasms 5Neurofibrosarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Dermatofibrosarcoma 4Clear-cell metastatic renal cell carcinoma 4Chondrosarcoma, Extraskeletal Myxoid 4Uterine Cervical Neoplasms 3Solid Tumors 3Small Cell Lung Carcinoma 3

Interventions

lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 5Temozolomide 4Specimen Handling 4Magnetic Resonance Spectroscopy 43-Iodobenzylguanidine 4anlotinib 3Everolimus 3olaparib 2cabozantinib 2belzutifan 2Sunitinib 2Phenoxybenzamine 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1talazoparib 1spartalizumab 1pembrolizumab 1pazopanib 1lanreotide 1guadecitabine 1fludarabine phosphate 1copper dotatate CU-64 1cixutumumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Paraganglioma × pazopanib × Clear all
NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

National Cancer Institute (NCI)

Phase 2 Terminated
7 enrolled 8 charts
CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡